Literature DB >> 21112624

The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma cells using targeted magnetoliposomes.

Stefaan J H Soenen1, Alain R Brisson, Eveline Jonckheere, Nele Nuytten, Sisareuth Tan, Uwe Himmelreich, Marcel De Cuyper.   

Abstract

The in vitro labeling of cultured cells with nanomaterials is a frequent practice but the efficiency, specificity and cytotoxicity of labeling specific cell types using targeted nanoparticles has only rarely been investigated. In the present work, functionalized anionic lipid-coated iron oxide cores (magnetoliposomes (MLs)) bearing galactose moieties were used for the specific labeling of asialoglycoprotein receptor 1 (ASGPR-1)-expressing HepG2 cells. The optimal number of galactose moieties per particle (± 26) was determined and uptake efficiency was compared with galactose-lacking anionic and cationic MLs. Using a blocking assay with free galactose, electron microscopy and co-cultures of HepG2 and non-ASGPR-1 expressing C17.2 cells, the specificity of the particles for the ASGPR-1 receptor was demonstrated. The intracellular localization of the galactose-bearing MLs was further verified by confocal microscopy. The non-toxic ML concentration was determined to be 400 μg Fe/ml. Finally, the use of these MLs for visualization of labelled cells by magnetic resonance imaging (MRI) was demonstrated. The data show a high uptake and specificity of the galactose-bearing MLs, whereas the cationic MLs remain primarily surface-associated. Thus, targeted MLs offer a successful alternative for cell labeling when cationic particles fail to be efficiently internalized. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112624     DOI: 10.1016/j.biomaterials.2010.11.005

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.

Authors:  Khaled Mahmoud; Shady Swidan; Mohamed El-Nabarawi; Mahmoud Teaima
Journal:  J Nanobiotechnology       Date:  2022-03-05       Impact factor: 10.435

2.  Triantennary GalNAc-Functionalized Multi-Responsive Mesoporous Silica Nanoparticles for Drug Delivery Targeted at Asialoglycoprotein Receptor.

Authors:  Rosemeyre Cordeiro; Ana Carvalho; Luísa Durães; Henrique Faneca
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

3.  Magnetic cell labeling of primary and stem cell-derived pig hepatocytes for MRI-based cell tracking of hepatocyte transplantation.

Authors:  Dwayne R Roach; Wesley M Garrett; Glenn Welch; Thomas J Caperna; Neil C Talbot; Erik M Shapiro
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

4.  Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma.

Authors:  Wan-Jiang Xue; Ying Feng; Fei Wang; Yi-Bing Guo; Peng Li; Lei Wang; Yi-Fei Liu; Zhi-Wei Wang; Yu-Min Yang; Qin-Sheng Mao
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

5.  Effect of PEGylation on Ligand-Targeted Magnetoliposomes: A Missed Goal.

Authors:  Joan Estelrich; Maria Antònia Busquets; María Del Carmen Morán
Journal:  ACS Omega       Date:  2017-10-09

6.  Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes.

Authors:  Rita Sofia Garcia Ribeiro; Sarah Belderbos; Pierre Danhier; Juan Gallo; Bella B Manshian; Bernard Gallez; Manuel Bañobre; Marcel de Cuyper; Stefaan J Soenen; Willy Gsell; Uwe Himmelreich
Journal:  Int J Nanomedicine       Date:  2019-07-29

7.  Magnetoliposomes with size controllable insertion of magnetic nanoparticles for efficient targeting of cancer cells.

Authors:  Won Il Choi; Abhishek Sahu; Frederik R Wurm; Seong-Min Jo
Journal:  RSC Adv       Date:  2019-05-14       Impact factor: 3.361

Review 8.  State of the Art of Stimuli-Responsive Liposomes for Cancer Therapy.

Authors:  Elmira Heidarli; Simin Dadashzadeh; Azadeh Haeri
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.